A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae
Antimicrobial Agents and Chemotherapy · 08.10.2024 · 68 (10)
DOI: 10.1128/aac.00208-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 08.10.2024. Verfasst von Mohamad Yasmin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Meropenem, Microbial Sensitivity Tests, beta-Lactamases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
We characterized the molecular determinants of meropenem–vaborbactam (MV) non-susceptibility among non-metallo-β-lactamase-producing KPC- Klebsiella pneumoniae (KPC- KP ). Whole-genome sequencing was performed to identify mutations associated with MV non-susceptibility. Isolates with elevated MV MICs were found to have mutations encoding truncated or altered OmpK36 porins and increased bla KPC copy numbers. KPC- KP isolates with decreased susceptibility to MV were detected among a collection of isolates predating the availability of MV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
- Department of Pathology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
- Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Case Western Reserve University-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
ORCID-Profile: Mohamad Yasmin, Liang Chen, Daniel D Rhoads, Michael R Jacobs, Laura J Rojas, David van Duin, Barry N Kreiswirth, Robert A Bonomo
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Yasmin, M., Marshall, S. H., Chen, L., Rhoads, D. D., Jacobs, M. R., Rojas, L. J., Perez, F., Hujer, A. M., Hujer, K. M., van Duin, D., Fowler, V., Chambers, H. F., Kreiswirth, B. N., Bonomo, R. A., & Antibacterial Resistance Leadership Group (2024). A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 68(10). https://doi.org/10.1128/aac.00208-24
Vancouver
Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, et al. A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2024;68(10). doi:10.1128/aac.00208-24
BibTeX
@article{Yasmin2024,
author = {Yasmin, Mohamad and Marshall, Steven H and Chen, Liang and Rhoads, Daniel D and Jacobs, Michael R and Rojas, Laura J and Perez, Federico and Hujer, Andrea M and Hujer, Kristine M and van Duin, David and Fowler, Vance and Chambers, Henry F and Kreiswirth, Barry N and Bonomo, Robert A and Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group},
title = {A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {10},
doi = {10.1128/aac.00208-24}
}
EUVIMED